BioVaria Startup Pitch & Partner Awards go to Exactmer and Lymphatica Medtech
This year’s hybrid BioVaria brought together over 230 life-science innovators – most of them live in Munich – boosting academia–industry partnering. Following two years of mainly virtual interaction, the event was well received by investors and decision makers from industry as well as academic inventors, entrepreneurs and their technology transfer partners.
Symbolic iage
pixabay.com
Over 60 licensable innovations were presented by leading academics and clinicians from all over Europe, from therapeutic and diagnostic approaches to platform technologies.
BioVaria’s interactive panel showcased 13 hand-picked start-ups, competing against each other for the StartUp Pitch & Partner Award. The winners, chosen by a jury of leading investors, are Exactmer in the category ‘Emerging’ and ‘Lymphatica Medtech’ in the category ‘Rising’.
Exactmer, a spin-out from Imperial College, London, UK, pursues a completely new approach to the synthesis of bio- and synthetic polymers for use in new medicines. Their proprietary technology allows the production of supremely accurate polymers at drastically reduced cost.
Lymphatica Medtech is a Swiss company developing medical devices for the treatment of lymphatic diseases. Its lead product LymphoDRAIN™, the first active implantable lymphatic shunt for the treatment of chronic lymphedema, has started clinical trials at the end of last year. If successful, it could increase the quality of life of millions of people suffering from lymphatic disease who have currently no therapeutic options other than life-long manual drainage and compression therapy.
‘I'm very honoured to have received the award among a cohort of impressive companies. Apart from this recognition, being able to participate in this outstanding event and foster communication with relevant investors face to face, are key elements for our company growth,’ said Marco Pisano, Co-Founder and CEO of Lymphatica Medtech.
‘Exactmer are delighted to have received the BioVaria Start Up Pitch and Partner Award. It was wonderful to meet such strong talents and innovators. It has been a truly inspiring event and we would like to thank the organisers for making it possible,‘ stated Dara O'Brien, Development and Operations Associate at Exactmer.
Another highlight of this year’s BioVaria was a special lecture by European Patent Office experts providing insights on patenting antibodies and vaccines.
Ascenion, who organized the event in collaboration with 14 European technology transfer organizations, is grateful to all partners, sponsors, speakers, moderators and participants who ensured the success and contributed to the vibrant spirit of this year’s BioVaria. ‘It’s almost like coming home,’ one of the sponsors said, reflecting the view of many participants who value the event not only for the outstanding quality of technologies and start-ups, but also for its trusting, almost familiar atmosphere.
The next BioVaria will be held on 24-25 April 2023 in Munich.
Other news from the department business & finance
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
Last viewed contents
Stone age hepatitis B virus decoded - Viral DNA shows the hepatitis B virus has been circulating in Europe for at least 7.000 years
Effects of chemical mixtures: Neurotoxic effects add up - Study demonstrates for the first time the toxicological relevance of chemical mixtures as they occur in humans
Innovative approach to treat autism spectrum disorders - University of Basel spin-off Translation-X receives Venture Kick funding
Shifting meetings, conventions online curbs climate change - The annual carbon footprint for the global event and convention industry is on par with the yearly greenhouse gas emissions of the entire U.S.
Photocure announces positive results of Phase 2B study evaluating Visonac in acne
Dental_porcelain
Rockeby awarded bird flu tests tender from Middle East
Rentschler focuses on biotechnology
How cancer genes become independent - Study sheds light on the mysterious evolution of DNA rings
